Ignite Creation Date:
2024-05-06 @ 3:51 PM
Last Modification Date:
2024-10-26 @ 1:58 PM
Study NCT ID:
NCT04785989
Status:
RECRUITING
Last Update Posted:
2023-11-18
First Post:
2021-02-25
Brief Title:
In Vivo Metabolic Profiling of CLL Chronic Lymphocytic Leukemia
Sponsor:
University of Wisconsin Madison
Organization:
University of Wisconsin Madison
Study Overview
Official Title:
Metabolic Profiling of Leukemic Cells Through Isotope Tracing in Patients with CLL
Status:
RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Metabolic reprogramming has been identified as a hallmark of cancer Almost a century after Otto Warburg initially discovered increased glycolytic activity in tumor tissue Warburg effect therapeutic targeting of cancer metabolism has become a field of intense research effort in cancer biology
A growing appreciation of metabolic heterogeneity and complexity is currently reshaping investigators simplistic understanding of metabolic reprogramming in cancer Discovering metabolic vulnerabilities as new treatment targets for cancer requires systematic dissection of metabolic dependencies fuel preferences and underlying mechanisms in the specific physiological context However todays data on cancer cell metabolic signatures and heterogeneity in their physiological habitat of the human organism is sparse to non-existent representing a critical knowledge gap in designing effective metabolic therapies Here the investigators propose a top-down approach studying cancer cell metabolism in patients followed by mechanistic in-depth studies in cell culture and animal models to define metabolic vulnerabilities
Investigators will develop a metabolic tracing method to quantitatively characterize metabolic signatures and fuel preferences of leukemic lymphocytes in patients with chronic lymphocytic leukemia CLL Isotopic metabolic tracers are nutrients that are chemically identical to the native nutrient Incorporated stable non-radioactive isotopes allow investigators to follow their metabolic fate by monitoring conversion of tracer nutrients into downstream metabolites using cutting-edge metabolomics analysis Using this method investigators propose to test the hypothesis that leukemic lymphocytes show tissue-specific metabolic preferences that differ from non-leukemic lymphocytes and that ex vivo in-plasma labeling represents a useful model for assaying metabolic activity in leukemic cells in a patient-specific manner
A growing appreciation of metabolic heterogeneity and complexity is currently reshaping investigators simplistic understanding of metabolic reprogramming in cancer Discovering metabolic vulnerabilities as new treatment targets for cancer requires systematic dissection of metabolic dependencies fuel preferences and underlying mechanisms in the specific physiological context However todays data on cancer cell metabolic signatures and heterogeneity in their physiological habitat of the human organism is sparse to non-existent representing a critical knowledge gap in designing effective metabolic therapies Here the investigators propose a top-down approach studying cancer cell metabolism in patients followed by mechanistic in-depth studies in cell culture and animal models to define metabolic vulnerabilities
Investigators will develop a metabolic tracing method to quantitatively characterize metabolic signatures and fuel preferences of leukemic lymphocytes in patients with chronic lymphocytic leukemia CLL Isotopic metabolic tracers are nutrients that are chemically identical to the native nutrient Incorporated stable non-radioactive isotopes allow investigators to follow their metabolic fate by monitoring conversion of tracer nutrients into downstream metabolites using cutting-edge metabolomics analysis Using this method investigators propose to test the hypothesis that leukemic lymphocytes show tissue-specific metabolic preferences that differ from non-leukemic lymphocytes and that ex vivo in-plasma labeling represents a useful model for assaying metabolic activity in leukemic cells in a patient-specific manner
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MSN240796 | OTHER_GRANT | None | None |
| SMPHMEDICINEHEM-ONC | OTHER | None | None |
| A534260 | OTHER | None | None |
| Protocol Version 10192022 | OTHER | None | None |
| 2020-1008 | OTHER | HSIRB UW Madison | None |